Remdesivir treatment and transient bradycardia in patients with coronavirus diseases 2019 (COVID-19). Issue 2 (August 2021)

• Record Type: Journal Article
• Authors: Pallotto, Carlo; Blanc, Pierluigi; Esperti, Sara; Suardi, Lorenzo Roberto; Gabbuti, Andrea; Vichi, Francesca; Mecocci, Lorenzo; Esposti, Anna Degli; Pierotti, Piera; Attala, Letizia; Salomoni, Elena; Baragli, Filippo; Francisci, Daniela; Pietro, Massimo Antonio Di
• Is Part Of: Journal of infection. Volume 83:Issue 2(2021)
• Page Start: 237
• Page End: 279
• Publication Date: 2021-08
• Subjects: Infection -- Periodicals; Bacterial Infections -- Periodicals; Communicable Diseases -- Periodicals; Electronic journals; 616.905
• DOI: 10.1016/j.jinf.2021.05.025
• Languages: English
• ISSNs: 0163-4453

Abstract

Highlights: Remdesivir is the only antiviral approved for COVID-19. Remdesivir treatment was associated with transient bradycardia. Bradycardia did not cause any severe clinical manifestation.